Ultime notizie per Nkarta (NASDAQ:NKTX) Azioni

NKARTA INC

Nkarta

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Nkarta Inc

Loop Capital analyst Mark Schappel initiates coverage on Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) with a Hold rating and announces Price Target of $320.

News

Price Target

Initiation

Analyst Ratings

ADSK

Loop Capital Initiates Coverage On Autodesk with Hold Rating, Announces Price Target of $320

Morgan Stanley analyst Lauren Schenk upgrades Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) from Underweight to Equal-Weight and raises the price target from $38 to $50.

Upgrades

ETSY

Morgan Stanley Upgrades Etsy to Equal-Weight, Raises Price Target to $50

Macro Economic Events

Economics

Treasury Secretary Bessent On Russia Says Would Urge Europe To Follow If We Implement Secondary Tariffs

Barclays initiates coverage on Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) with a Equal-Weight rating and announces Price Target of $173.

Barclays Initiates Coverage On Sprouts Farmers Market with Equal-Weight Rating, Announces Price Target of $173

Seaport Global analyst Jay Goldberg upgrades Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) from Sell to Neutral.

Seaport Global Upgrades Analog Devices to Neutral

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Pfizer Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 7.03%</li>
<li>Guggenheim analyst Vamil Divan reiterated a Buy rating on March 18, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and slashed the price target from $30 to $29 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: The Bristol Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) and Pfizer alliance announced a new direct-to-patient option for purchasing Eliquis (apixaban) via the alliance's patient resource, Eliquis 360 Support, on July 17.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest PFE <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="907" height="825" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272.png" alt="" class="wp-image-993503" style="width:605px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074324/image-272-768x699.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.29%</li>
<li>Truist Securities analyst David Macdonald maintained a Buy rating and raised the price target from $82 to $84 on May 12, 2025. This analyst has an accuracy rate of 63%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $67 to $71 on May 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Recent News: CVS Health will hold a conference call on Thursday, July 31, to discuss second quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest CVS <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273.png" alt="" class="wp-image-993506" style="width:572px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074355/image-273-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 3.47%</li>
<li>Citigroup analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $210 to $205 on May 14, 2025. This analyst has an accuracy rate of 63%.</li>
<li>Guggenheim analyst Vamil Divan maintained a Buy rating and increased the price target from $214 to $216 on April 29, 2025. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: GI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc., and AbbVie, on July 10, announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT protein platform, for oncology and autoimmune diseases.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest ABBV <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0721"><img loading="lazy" decoding="async" width="910" height="828" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274.png" alt="" class="wp-image-993508" style="width:576px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/21074437/image-274-768x699.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ABBV

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Seaport Global analyst Jay Goldberg upgrades Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) from Sell to Neutral.

Seaport Global Upgrades Texas Instruments to Neutral

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/07/18/final-trades-rtx-netflix-and-freeport-mcmoran.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss, Chief Investment Officer and Managing Partner of Short Hills Capital Partners, picked Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) as his final trade.
On July 17, Netflix reported second-quarter revenue of $11.08 billion, up 16% year-over-year. The revenue total beat a Street consensus estimate of $11.04 billion, according to data from Benzinga Pro. The company reported second-quarter earnings per share of $7.19, beating a Street consensus estimate of $7.06.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson, Capital Wealth Planning founder and CIO, named RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) amid incredible demand for aerospace repair.
RTX will release earnings results for the second quarter before the opening bell on Tuesday, July 22. Analysts expect the company to report quarterly earnings at $1.43 per share on revenue of $20.67 billion.
Supporting his view, Morgan Stanley analyst Kristine Liwag maintained RTX with an Equal-Weight rating on July 17 and raised the price target from $135 to $165.
Jenny Van Leeuwen Harrington, Chief Executive Officer of Gilman Hill Asset Management, LLC, named Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) as her final trade.
Lending support to his choice, Freeport-McMoRan, on April 24, reported better-than-expected first-quarter sales results. Revenue stood at $5.73 billion, beating the consensus of $5.44 billion. Copper sales volumes totaled 872 million pounds, which exceeded the January 2025 estimate.
Price Action:
<ul class="wp-block-list">
<li>RTX shares closed at $151.50 on Friday.</li>
<li>Netflix shares dipped 5.1% to settle at $1,209.24 during the session.</li>
<li>Freeport-McMoRan shares rose 0.8% to close at $44.80 during the session.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

NFLX

Netflix, RTX And A Basic Materials Stock On CNBC's 'Final Trades'

Commodities

Treasury Secretary Bessent On China Says Could Start Discussing Iranian Oil

Amneal Pharmaceuticals, Inc. ("Amneal") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) announced that its subsidiary, Amneal Pharmaceuticals LLC (the "Issuer"), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans (the "new term B loans") under a new term loan facility (the "Term Loan Facility"). The Issuer has also launched an offering of $750 million aggregate principal amount of senior secured notes due 2032 (the "notes") in a private offering.
The Issuer intends to use the net proceeds of the new term B loans and the notes to refinance its existing term B loans in full, to repay a portion of outstanding amounts borrowed under its ABL facility and to pay related fees, premiums and expenses. The offering of the notes is not conditioned on entry into the Term Loan Facility.

AMRX

Amneal Pharma's Subsidiary Pursues $1.8B Term Loan Facility, Launches $750M Senior Secured Notes Offering

The ground shook for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) last week as the U.S. Food and Drug Administration (FDA), alarmed by a third patient death tied to its gene therapy platform, pulled a rare move: requesting a voluntary halt to Elevidys shipments. The company&#8217;s response? A resounding &#8220;no,&#8221; igniting a major regulatory clash with severe implications for patients and investors alike.
The upheaval began on Friday when the U.S. Food and Drug Administration (FDA) <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46497110/sareptas-setback-deepens-with-another-gene-therapy-fatality">made a rare and impactful</a> announcement: it had placed Sarepta&#8217;s investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold. This decision stemmed from serious safety concerns, including three patient deaths potentially linked to these products, indicating that study participants faced or would be exposed to an unreasonable and significant risk of illness or injury.
In light of these developments, the FDA also formally <a href="https://www.fda.gov/news-events/press-announcements/fda-requests-sarepta-therapeutics-suspend-distribution-elevidys-and-places-clinical-trials-hold">requested</a> Sarepta to voluntarily halt all shipments of Elevidys, the company&#8217;s approved gene therapy. However, in a move that set the stage for a major regulatory clash with severe implications for both patients and investors, Sarepta definitively refused this request.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/46101643/did-the-fda-make-a-mistake-sareptas-elevidys-approval-under-scrutiny" target="_blank" rel="noreferrer noopener">Did The FDA Make A Mistake? Sarepta&#8217;s Elevidys Approval Under Scrutiny</a>
The three fatalities, which prompted the FDA&#8217;s strong action, have resulted from acute liver failure in individuals who had received either Elevidys or an investigational gene therapy utilizing the same AAVrh74 serotype, a viral vector used in gene delivery. Notably, one of these deaths occurred during a clinical trial for LGMD, conducted under an investigational new drug application.
Adding to Sarepta&#8217;s challenges, the FDA further revoked the platform technology designation for the company&#8217;s AAVrh74 Platform Technology. This designation, typically granted to technologies with broad therapeutic promise that can streamline regulatory review, was rescinded because, given the new safety information, the preliminary evidence was deemed insufficient to demonstrate that the AAVrh74 Platform Technology could be incorporated into or utilized by multiple drugs <a href="https://www.benzinga.com/general/health-care">without adverse effects on safety</a>.
Elevidys had received traditional approval in June 2024 for ambulatory Duchenne muscular dystrophy (DMD) patients aged four years and older with a confirmed DMD gene mutation. Previously, in June 2023, it secured accelerated, conditional approval for non-ambulatory DMD patients. However, continued approval for non-ambulatory patients is contingent upon verification of clinical benefit through confirmatory trials. 
With the emergence of this new safety data, the FDA notified Sarepta that Elevidys&#8217;s indication should now be restricted solely to ambulatory patients. The FDA is continuing its investigation into the risk of acute liver failure, including severe outcomes such as hospitalization and death, associated with gene therapies employing Sarepta&#8217;s AAVrh74 Platform Technology, and is prepared to take further regulatory actions as necessary.
Despite the FDA&#8217;s stance, Sarepta issued a <a href="https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-provides-statement-elevidys">statement</a> on Friday affirming its decision to continue shipping Elevidys to the ambulatory patient population. The company asserted that its &#8220;comprehensive scientific interpretation of the data… shows no new or changed safety signals in the ambulant patient population.&#8221; Sarepta also expressed its commitment to ongoing discussions and information sharing with the FDA to advance their &#8220;shared purpose of protecting patient safety and informed access to care.&#8221;
The company clarified that the most recent fatal event occurred in a Phase 1 clinical trial for an investigational gene therapy called SRP-9004, which is designed to treat a different condition, LGMD Type 2D. Sarepta emphasized that SRP-9004 is administered at a different dose and manufactured using a distinct process from Elevidys. Furthermore, the LGMD study participant who passed away was not treated with Elevidys, and dosing for the SRP-9004 trial had already concluded at the time of death. Sarepta reported this acute liver failure (ALF) event as a life-threatening case to the FDA on June 20 and subsequently notified the agency of the death on July 3.
Looking ahead, Sarepta plans to submit the findings of an expert panel and a proposed protocol to the FDA. They will also discuss a proposal to collect additional data on a modified treatment regimen in a new cohort (Cohort 8) of the ENDEAVOR study (Study SRP-9001-103). This is intended as a pathway to re-establish dosing for <a href="https://www.benzinga.com/news/fda/25/07/46473418/sarepta-therapeutics-reorganization-boosts-investor-confidence">non-ambulant patients</a> in the future. 
Price Action: As of Monday&#8217;s premarket session, Sarepta&#8217;s stock was down 6.79% at $13.12, reflecting the ongoing concerns and market reaction to these significant developments.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/eurozone/25/07/46514335/chrysler-jeep-parent-company-stellantis-expects-2-7-billion-net-loss-in-first-half-of-2025-as-trump-tariffs-cause-uncertainty" target="_blank" rel="noreferrer noopener">Chrysler, Jeep Parent Company Stellantis Expects $2.7 Billion Net Loss In First Half Of 2025 As Trump Tariffs Cause Uncertainty</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Movers

General

SRPT

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

Keefe, Bruyette &amp; Woods analyst Wood Lay initiates coverage on John Marshall Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JMSB#NASDAQ">JMSB</a>) with a Outperform rating and announces Price Target of $22.

JMSB

Keefe, Bruyette & Woods Initiates Coverage On John Marshall Bancorp with Outperform Rating, Announces Price Target of $22

Stephens &amp; Co. analyst Terry McEvoy maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Overweight and raises the price target from $24 to $29.

Stephens & Co. Maintains Overweight on Regions Finl, Raises Price Target to $29

– Results Reflect Continued Financial Strength and Deleveraging –
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>) ("Amneal" or the "Company") today announced certain unaudited preliminary financial results for the second quarter ended June 30, 2025. The Company plans to report actual second quarter 2025 financial results on August 5, 2025.
Unaudited Preliminary Financial Results for the Second Quarter Ended June 30, 2025
<ul>
<li>Net revenue of $720 million to $730 million, an increase of approximately 3% versus the same period in 2024 &nbsp;</li>
<li>Income before income taxes of $45 million to $56 million, versus $20 million in the same period in 2024 &nbsp;</li>
<li>Adjusted EBITDA of $180 million to $185 million, an increase of approximately 13% versus the same period in 2024 &nbsp;</li>
<li>Gross leverage decreased to 3.8x as of June 30, 2025, compared to 4.1x as of December 31, 2024, and net leverage decreased to 3.7x as of June 30, 2025, compared to 3.9x as of December 31, 2024, due to higher profitability and continued debt reduction</li>
</ul>

Guidance

Amneal Pharma Preliminary Q2 Net Revenue $720M - $730M, Up ~3% YoY; Adj. EBITDA $180M - $185M, Up ~13% YoY

Bessent Says Trade Talks Are Moving Along, Quality Of Deals More Important Than Timing

Stephens &amp; Co. analyst Andy Terrell maintains WaFd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFD#NASDAQ">WAFD</a>) with a Equal-Weight and raises the price target from $32 to $33.

WAFD

Stephens & Co. Maintains Equal-Weight on WaFd, Raises Price Target to $33

The Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/KO/earnings">opening bell on Tuesday, July 22.</a>
Analysts expect the beverage company to report quarterly earnings of 84 cents per share, compared to 84 cents per share in the year-ago period. Coca-Cola projects to report quarterly revenue of $12.55 billion, compared to $12.31 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 18, Coca-Cola named Luisa Ortega as president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026.
With the recent buzz around Coca-Cola, some investors may be eyeing potential gains from the company's dividends. As of now, Coca-Cola offers an annual dividend yield of 2.92%. That&#8217;s a semi-annual dividend amount of 51 cents per share ($2.04 a year).  
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $205,429 or around 2,941 shares. For a more modest $100 per month or $1,200 per year, you would need $41,072 or around 588 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($2.04 in this case). So, $6,000 / $2.04 = 2,941 ($500 per month), and $1,200 / $2.04 = 588 shares ($100 per month).
Note that dividend yield can change on a rolling basis; the dividend payment and the stock price fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
KO Price Action: Shares of Coca-Cola fell 1.1% to close at $69.85 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46491269/top-2-energy-stocks-that-may-fall-off-a-cliff-this-quarter-2">Top 2 Energy Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>
Image: Shutterstock

Earnings

Dividends

How To Earn $500 A Month From Coca-Cola Stock Ahead Of Q2 Earnings

Keefe, Bruyette &amp; Woods analyst Bose George initiates coverage on Jefferson Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JCAP#NASDAQ">JCAP</a>) with a Outperform rating and announces Price Target of $22.

JCAP

Keefe, Bruyette & Woods Initiates Coverage On Jefferson Capital with Outperform Rating, Announces Price Target of $22

<ul>
<li>DeFi Technologies has launched its DeFi Advisory business line to provide institutional-grade digital asset treasury solutions for public companies, offering asset management, trade execution, and strategic advisory through an integrated platform.&nbsp; &nbsp;</li>
<li>The Advisory division's first mandate is with&nbsp;Nuvve Holding Corp., which has appointed DeFi Technologies to manage its HYPE token treasury strategy, including custody, OTC execution via Stillman Digital, and performance optimization. &nbsp;</li>
<li>DeFi Technologies will earn recurring management fees based on treasury AUM, paid quarterly in either equity or cash, reinforcing the Company's scalable, fee-based business model as public market participation in digital assets accelerates.</li>
</ul>
TORONTO, July 21, 2025 /PRNewswire/ -&nbsp;DeFi Technologies Inc. (the "Company" or "DeFi Technologies") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance, is pleased to announce that its newly launched DeFi Advisory business line has been engaged to act as the asset manager for Nuvve Holding Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) recently announced HYPE treasury strategy.

DEFT

NVVE

DeFi Technologies' DeFi Advisory Business Line Engaged To Act As Asset Manager For Nuvve Holding's HYPE Treasury Strategy

The South Korea-led investigation into December's fatal Jeju Air crash, which caused over 179 deaths, says that the pilots turned off the less-damaged left engine after a bird strike.
What Happened: "The investigation team has clear evidence and backup data, so its finding will not change," a source said, cited by Reuters in its report on Monday.
The evidence, including a physical engine switch, cockpit voice recorder, as well as computer data, shows that the pilots turned off the left engine instead of the right engine after the bird strike as part of emergency safety protocols, the report said.
The investigators briefed the families of the victims on Saturday and planned to release a preliminary report, but were met with objections by the victims' families.
The lawyers representing the families claimed that their clients feel the report "appeared to apportion blame to the pilots without exploring other contributing factors," the report said.
The representatives of the victims' families, as well as the Jeju Air pilots' union, have also said that the embankments at the Muan airport also need to be investigated, which experts believe could have contributed to the higher death toll, the report says.
The pilots' union also accused investigators of trying to make the pilots "scapegoats" by saying that there was minimal damage to the left engine, when both engines showcased bird remains, the union said.
Why It Matters: The report comes as air crash reports involving Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) Aircraft have been in the news lately. South Korean authorities ordered all airlines in the country <a href="https://www.benzinga.com/markets/equities/25/07/46387516/boeing-stock-rises-premarket-despite-fuel-switch-checks-planned-by-south-korea-air-india-ceo-says-probe-far-from-over">to conduct checks</a> on the fuel switches on Boeing Aircraft in the country.
This comes in despite the FAA and Boeing saying that <a href="https://www.benzinga.com/news/topics/25/07/46384959/faa-boeing-say-fuel-switch-locks-on-787-dreamliner-are-safe-amid-air-india-crash-probe">the fuel switch locks</a> on Boeing aircraft were safe, as reports emerged that fuel supply to the engine on board the Boeing 787-Dreamliner was <a href="https://www.benzinga.com/news/topics/25/07/46380354/fuel-supply-was-cut-moments-before-air-india-crash-as-per-preliminary-report">abruptly cut off</a> in the moments leading up to <a href="https://www.benzinga.com/markets/25/06/45911791/boeing-dreamliner-carrying-over-200-passengers-crashes-shortly-after-takeoff-near-indias-ahmedabad-b">last month's fatal crash</a> in the Indian city of Ahmedabad.
Elsewhere, U.S. Transportation Secretary Sean Duffy said that the Trump administration would require <a href="https://www.benzinga.com/news/politics/25/07/46461080/sean-duffy-says-trump-administration-would-require-an-additional-19-billion-to-overhaul-air-traffic-control-need-more-money">an additional $19 billion</a> to overhaul the aging Air Traffic Control system in the U.S.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/06/46133937/boeing-787-dreamliner-crash-india-shuts-door-on-un-aviation-expert-probing-plane-accident">Boeing 787 Dreamliner Crash: India Shuts Door On UN Aviation Expert Probing Plane Accident</a></li>
</ul>
Image Courtesy: Thanhliemnguyen / Shutterstock.com

Comments

Nkarta

Notizie

Ultime notizie per Nkarta (NASDAQ:NKTX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO